scholarly journals A Rare Case of the Simultaneous, Multifocal, Metastatic Renal Cell Carcinoma to the Ipsilateral Left Testes, Bladder, and Stomach

2016 ◽  
Vol 2016 ◽  
pp. 1-3 ◽  
Author(s):  
Michael Kongnyuy ◽  
Samuel Lawindy ◽  
Daniel Martinez ◽  
Justin Parker ◽  
Mary Hall
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Rare Case ◽  
Simultaneous Presentation ◽  
Cell Renal Cell Carcinoma ◽  
Diagnostic Endoscopy ◽  
Surveillance Imaging ◽  
History Of

We describe the rare case of a 68-year-old gentleman with the history of a hand-assisted laparoscopic left radical nephrectomy for a T2bN0M1 clear cell renal cell carcinoma (RCC). Seven years after surgery and with clean surveillance imaging for metastasis/recurrence the patient presented with three separate tumors suspicious for malignancy. A bladder lesion was found during workup for hematuria, a stomach lesion during diagnostic endoscopy, and a testicular lesion during self-exam. He underwent transurethral resection of bladder tumor, left inguinal orchiectomy, and upper endoscopic ensnarement. All specimens surprisingly showed RCC by histology and immunostaining. These three sites are rare for RCC metastasis and simultaneous presentation is even rarer, further emphasizing the importance of continuous and careful follow-up in this patient population, despite what could appear as complete remission.

scholarly journals Rare Case of Clear Cell Renal Cell Carcinoma Metastasizing to Contralateral Kidney and Ipsilateral Parotid more than five Years following Nephrectomy

2019 ◽  
Vol 23 (2) ◽  
pp. 108-111
Author(s):  
Guy Sydney ◽  
Kalliopi Ioakim ◽  
Nayia Kara ◽  
George Pantelas
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Rare Case ◽  
Clear Cell ◽  
Histopathological Diagnosis ◽  
Cell Renal Cell Carcinoma ◽  
Contralateral Kidney ◽  
History Of ◽  
Patient’S History

Summary Backgroung/Aim: Salivary gland malignancies are rare, with only a fraction due to metastases. We report a rare case of the Clear Cell Renal Cell Carcinoma (CCRCC), a subtype of the Renal Cell Carcinoma (RCC), metastasizing to the parotid gland more than five years following nephrectomy. Case report: A 75-year-old female presented with a unilateral left parotid mass that was growing over the period of 18 months. After clinical and laboratory examinations, the patient underwent left partial superficial parotidectomy with preservation of the facial nerve. The significance of the patient’s history of the CCRCC was pivotal to the histopathological diagnosis of a metastatic CCRCC to the parotid. Conclusions: The unpredictable nature of the RCC results in the need for a long period of follow-up, as well as having a high degree of suspicion of metastasis in a patient presenting with a medical history of the RCC and a parotid mass.

scholarly journals Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma

2018 ◽  
Vol 5 (4) ◽  
pp. 6-13 ◽  
Author(s):  
Juan Chipollini ◽  
Mounsif Azizi ◽  
Charles C Peyton ◽  
Dominic H Tang ◽  
Jasreman Dhillon ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Type I ◽  
Cell Renal Cell Carcinoma ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Papillary Type

The purpose of this study was to assess the prognostic value of programmed death ligand-1 (PD-L1) positivity in a non-clear cell renal cell carcinoma (non-ccRCC) cohort. PD-L1 expression was evaluated by immunohistochemistry (IHC) using formalin-fixed paraffin-embedded (FFPE) specimens from 45 non-ccRCC patients with available tissue. PD-L1 positivity was defined as ?1% of staining. Histopathological characteristics and oncological outcomes were correlated to PD-L1 expression. Cancer-specific survival (CSS) and recurrence-free survival (RFS) stratified by PD-L1 status were estimated using the Kaplan–Meier method. Median age was 58 years and median follow-up was 40 months. Non-ccRCC subtypes included sarcomatoid (n = 9), rhabdoid (n = 6), medullary (n = 2), Xp11.2 translocation (n = 2), collecting duct (n = 1), papillary type I (n = 11), and papillary type II (n = 14). PD-L1 positivity was noted in nine (20%) patients. PD-L1 positivity was significantly associated with higher Fuhrman nuclear grade (P = 0.048) and perineural invasion (P = 0.043). Five-year CSS was 73.2 and 83% for PD-L1 positive and negative tumors, respectively (P = 0.47). Five-year RFS was 55.6 and 61.5% for PD-L1 positive and negative tumors, respectively (P = 0.58). PD-L1 was expressed in a fifth of non-ccRCC cases and was associated with adverse histopathologic features. Expression of biomarkers such PD-L1 may help better risk-stratify non-ccRCC patients to guide treatment decisions and follow-up strategies.

Non-osseous soft tissue metastasis in the foot from renal cell carcinoma

2020 ◽  
Vol 13 (10) ◽  
pp. e236051
Author(s):  
Nusrat Jahan ◽  
Shabnam Rehman
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Soft Tissues ◽  
Imaging Techniques ◽  
Musculoskeletal Symptoms ◽  
Systematic Evaluation ◽  
Pathological Examination ◽  
Cell Renal Cell Carcinoma ◽  
History Of

Metastatic tumours of the distal extremities, also known as acrometastases, are rare. The majority of the acrometastases involve bones—involvement of the soft tissues of the feet and hands is extremely rare. We report a case of clear cell renal cell carcinoma metastasised to the soft tissues of the foot. The patient presented with pain and swelling in his right foot. Diagnosis of acrometastases frequently gets delayed due to the rarity of this condition and resultant low clinical suspicion. Possibility of metastatic disease should be entertained as an important differential diagnosis when patients with a history of cancer present with musculoskeletal symptoms. A systematic evaluation incorporating thorough clinical assessment, advanced imaging techniques like MRI and pathological examination is critical to establish the diagnosis.

Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 482-482 ◽  
Author(s):  
Raphael Brandao Moreira ◽  
Rana R. McKay ◽  
Wanling Xie ◽  
Daniel Yick Chin Heng ◽  
Guillermo de Velasco ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Clinical Activity ◽  
Significant Activity ◽  
Cell Renal Cell Carcinoma ◽  
Treatment Naïve ◽  
Retrospective Multicenter Study

482 Background: PD1/PDL1 inhibitors have shown significant activity in the treatment of patients (pts) with metastatic clear cell renal cell carcinoma (ccRCC), but their activity in nccRCC is poorly characterized. Methods: We conducted a retrospective multicenter study of pts with metastatic nccRCC treated with PD1/PDL1 inhibitors. Baseline clinical parameters, overall response rate (ORR) by RECIST, time-to-treatment failure (TTF), and overall survival (OS) were summarized. Results: We identified 40 pts across 8 academic institutions. Fourteen (35%) had papillary histology, 10 (25%) chromophobe, 3 (8%) translocation, and 7 (18%) unclassified. Six (16%) had ccRCC with a sarcomatoid component > 30%. 20% had International Metastatic RCC Database Consortium (IMDC) favorable-risk disease, 60% intermediate, and 20% poor-risk. Ten (25%) were treatment-naïve and the majority received PD1/PDL1 monotherapy (n=30, 75%), while the remaining received a combination of PD1/PDL1 with anti-VEGF(R) or anti-CTLA4 therapy. ORR for the total cohort was 18% and 10% for PD1/PDL1 monotherapy pts (Table). With a median follow-up of 5.6 months, the overall median TTF was 4.7 months (2.9-15.9) and six-month OS was 81% (60-91%). Conclusions: PD1/PDL1 blockade resulted in some activity in pts with various nccRCC histologies. In the absence of available clinical trials, this data may support the use of PD1/PDL1 blocking agents in pts with nccRCC. [Table: see text]

scholarly journals High Cytoplasmic and Membranous Versus Nuclear Talin-1 Expression Associated With Malignancy Potential and Poor Survival in Clear Cell Renal Cell Carcinoma

2021 ◽  
Author(s):  
Leili Saeednejad Zanjani ◽  
Somayeh Vafaei ◽  
Maryam Abolhasani ◽  
Fahimeh Fattahi ◽  
Zahra Madjd
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Tissue Microarrays ◽  
Cell Renal Cell Carcinoma ◽  
Free Survival ◽  
Cytoplasmic Expression ◽  
Tissue Specimens

Abstract Using bioinformatics analysis Talin-1 protein was indicated as a potential prognostic focal adhesion factor in renal cell carcinoma (RCC). We, therefore, examined its protein expression levels and prognostic significant of Talin-1 with clinical follow-up in total of 269 tissue specimens from three important subtypes of RCC and 30 adjacent normal samples using tissue microarrays (TMAs). Then, we used combined analysis with B7-H3 to confirm that Talin-1 may be related to metastasis. The results showed that high membranous and cytoplasmic expression of Talin-1 was significantly associated with advanced nucleolar grade (P < 0.001, all), microvascular invasion (P = 0.007, P = 0.004, respectively), histological tumor necrosis (P = 0.020, P = 0.018), and invasion to Gerota’s fascia (P = 0.025, P = 0.050) in ccRCC. In addition, high membranous and cytoplasmic expression of Talin-1 was associated with significantly poorer disease-specific survival (P = 0.043, P = 0.024, respectively) and progression- free survival (P = 0.046, in cytoplasm). Moreover, increased cytoplasmic expression of Talin-1 High/B7-H3 High compared to the other phenotypes was associated with poor prognosis and progression of the disease in patients with distant metastasis. Collectively, these observations indicate that Talin-1 is an important molecule involved in the spread and progression of ccRCC when expressed particularly in cytoplasm and may serve as a novel prognostic biomarker in this subtype.

Sign in / Sign up

Export Citation Format

Share Document